The first thing you see on the Atomic Alchemy website is a black-and-white photograph of a glowing, blue Cherenkov radiation pool. The company's tagline is: "Building scalable U.S. radioisotope production capabilities." It is a hard, physical, and historically intimidating technology, framed as a solution to a quietly critical supply problem.
Atomic Alchemy's product is the radioisotopes themselves. These unstable atoms, produced by irradiating target materials inside a reactor, are the active ingredients in millions of cancer treatments and diagnostic scans every year. For decades, the U.S. has been largely dependent on foreign sources for its supply. Atomic Alchemy's bet is that this dependency is a national vulnerability, and that a new generation of small, dedicated, non-power reactors can carve out a domestic niche.
The wedge is a dedicated reactor
Atomic Alchemy's approach is focused on the Versatile Isotope Production Reactor, or VIPR, a 15-megawatt thermal light-water reactor designed from the ground up to make isotopes [ANS / Nuclear Newswire, 2025-11-14]. The company has requested permission from the Nuclear Regulatory Commission to build four such non-power reactors at the Idaho National Laboratory [ANS / Nuclear Newswire, 2025-11-24].
A reactor optimized for isotope production can be more flexible, efficient, and reliable for this single purpose than a massive power plant running a side business. The company already holds an NRC license to process radium-226 at its Idaho Falls laboratory [World Nuclear News].
A founder with four decades in the core
The company is the vision of Thomas Eiden, a nuclear engineer with over four decades of experience in power generation and project development [LinkedIn, Thomas Eiden, 2026]. His background is in the world of national laboratories and reactor core design [thomaseiden.com]. Eiden's public engagement is focused on the specifics of production and regulation, a tone that matches the company's target customers: radiopharmacies, research institutions, and government agencies.
The Oklo acquisition and the path to scale
In February 2025, Atomic Alchemy was acquired by Oklo Inc. in an all-stock transaction valued at an estimated $25 million [Businesswire, 20250305]. The deal was framed as a strategic combination: Oklo gets a foothold in the isotope production market and a team with deep regulatory experience, while Atomic Alchemy gains the capital and backing of a publicly-traded company.
| Entity | Role | Key Detail |
|---|---|---|
| Thomas Eiden | Founder & CEO | Nuclear engineer with 44 years in power generation [LinkedIn, Thomas Eiden, 2026]. |
| Oklo Inc. | Acquirer (2025) | Advanced fission company that acquired Atomic Alchemy [Businesswire, 20250305]. |
| Y Combinator | Investor (Seed) | Participated in the startup's early seed funding round [Y Combinator]. |
| U.S. Nuclear Regulatory Commission | Regulator | Granted license for radium-226 processing; application for four VIPR reactors pending [World Nuclear News] [ANS / Nuclear Newswire, 2025-11-24]. |
The risks in a hardened market
Building a new nuclear facility in the United States is a capital-intensive and legally complex endeavor. Atomic Alchemy's bet rests on navigating this gauntlet successfully.
- Regulatory friction. The NRC application process for four new reactors is measured in years. Any delay or redesign can burn capital.
- Capital intensity. The actual construction of multiple reactors represents a financial commitment far beyond the startup's initial seed funding [CB Insights].
- Market competition. The company is competing against entrenched, subsidized international producers and a handful of large domestic players.
What to watch in Idaho
The next milestones for Atomic Alchemy are concrete and regulatory. The NRC's decision on the permit for the four VIPR reactors will be the most significant signal. Second, watch for the first commercial isotope shipments from its existing licensed facility. Finally, the integration with Oklo will be telling. The success of this model will determine whether this is a true acquisition of capability or merely an asset purchase.